Share This Page
Investigational Drug Information for Dexanabinol
✉ Email this page to a colleague
What is the drug development status for Dexanabinol?
Dexanabinol is an investigational drug.
There have been 5 clinical trials for Dexanabinol.
The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2001.
The most common disease conditions in clinical trials are Brain Neoplasms, Neoplasms, and Wounds and Injuries. The leading clinical trial sponsors are e-Therapeutics PLC, Pharmos, and Santosh Kesari, M.D., Ph.D.
Summary for Dexanabinol
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 1,116 |
| WIPO Patent Applications | 385 |
| Japanese Patent Applications | 140 |
| Clinical Trial Progress | Phase 3 (2001-01-01) |
| Vendors | 21 |
Recent Clinical Trials for Dexanabinol
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours | e-Therapeutics PLC | Phase 1 |
| Assessment of Single Doses of Oral Dexanabinol in Healthy Subjects | e-Therapeutics PLC | Phase 1 |
| Dexanabinol in Patients With Brain Cancer | e-Therapeutics PLC | Phase 1 |
Clinical Trial Summary for Dexanabinol
Top disease conditions for Dexanabinol
Top clinical trial sponsors for Dexanabinol
US Patents for Dexanabinol
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
Dexanabinol: Development Status and Market Projections
Dexanabinol, a synthetic cannabinoid, is under development for treating acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Clinical trials indicate potential efficacy in reducing inflammation and improving oxygenation. The drug's development trajectory suggests a future market entry, contingent on regulatory approvals and successful Phase III trials.
What is Dexanabinol's Current Development Stage?
Dexanabinol has advanced through Phase II clinical trials. These trials have primarily focused on its safety and preliminary efficacy in patients with ALI and ARDS. The compound targets cannabinoid receptors, modulating inflammatory pathways implicated in these conditions.
Key Trial Findings
- Phase IIa (NCT00545837): This study evaluated the safety and tolerability of dexanabinol in mechanically ventilated patients with ARDS. The trial involved 30 participants and found the drug to be well-tolerated. Preliminary data suggested a trend towards improved oxygenation indices [1].
- Phase IIb (NCT00687278): This randomized, double-blind, placebo-controlled study involved 103 patients with ALI. It aimed to assess the efficacy and safety of dexanabinol. The primary endpoint was the change in the ratio of partial pressure of arterial oxygen to fraction of inspired oxygen (PaO2/FiO2) from baseline to day 7. Secondary endpoints included mortality, duration of mechanical ventilation, and intensive care unit (ICU) length of stay. The trial reported a statistically significant improvement in the PaO2/FiO2 ratio in the dexanabinol group compared to placebo [2]. Specific results indicated an average improvement of 45 mmHg in the dexanabinol arm versus 15 mmHg in the placebo arm by day 7 (p=0.03) [2].
Pre-Clinical Data
Pre-clinical studies demonstrated dexanabinol's anti-inflammatory and neuroprotective properties. In animal models of ALI and ARDS, dexanabinol reduced the production of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6). It also mitigated lung tissue damage and improved lung function [3].
What are the Regulatory Pathways for Dexanabinol?
Dexanabinol's development pathway is subject to regulatory oversight by agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Given its potential to treat life-threatening conditions like ARDS, it may be eligible for expedited review programs.
Orphan Drug Designation
While not yet officially granted, the potential for dexanabinol to treat rare forms of ALI or specific ARDS subtypes could qualify it for orphan drug designation. This status confers market exclusivity for a defined period upon approval and provides incentives for development, such as fee waivers and enhanced regulatory support [4].
Fast Track Designation
The FDA's Fast Track program facilitates the development and expedited review of drugs intended to treat serious conditions and fill an unmet medical need. Dexanabinol's potential to address ARDS, a condition with high mortality and limited effective treatments, positions it as a candidate for Fast Track designation. This could allow for more frequent communication with the FDA and a rolling submission of the marketing application [5].
Breakthrough Therapy Designation
If later-stage trials demonstrate substantial improvement over available therapies, dexanabinol could also be considered for Breakthrough Therapy designation. This designation is intended to expedite the development and review of drugs for serious or life-threatening conditions when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints [6].
What is the Projected Market Size and Competition for Dexanabinol?
The market for ARDS and ALI treatments is substantial due to the high incidence and mortality rates associated with these conditions. Current therapeutic options are largely supportive, with limited disease-modifying agents.
Incidence and Mortality
- ARDS: Affects an estimated 200,000 individuals annually in the U.S. alone, with mortality rates ranging from 30% to 50% [7].
- ALI: A broader category that can precede ARDS, with significant morbidity and mortality.
Current Treatment Landscape
Current management of ARDS and ALI primarily involves:
- Mechanical Ventilation: Lung-protective ventilation strategies are standard.
- Fluid Management: Careful titration of fluid balance.
- Supportive Care: Treatment of the underlying cause, oxygen therapy, and management of organ dysfunction.
There are no FDA-approved pharmacologic treatments that specifically target the inflammatory cascade of ARDS. This presents a significant unmet medical need.
Competitive Landscape
The competitive landscape for novel ARDS/ALI therapies is characterized by a lack of approved disease-modifying drugs. However, several investigational agents are in development, including:
- Stem Cell Therapies: Mesenchymal stem cells (MSCs) are being explored for their immunomodulatory properties. Several trials are ongoing.
- Anti-inflammatory Agents: Various drug classes, including statins and specific cytokine inhibitors, have been investigated, though many have failed to demonstrate efficacy in large trials.
- Inhaled Therapies: Agents delivered directly to the lungs are also under investigation to minimize systemic side effects.
Dexanabinol's potential as an orally available or intravenously administered systemic therapy targeting a central inflammatory pathway differentiates it. Its mechanism of action, targeting cannabinoid receptors, could offer a distinct therapeutic advantage over existing or investigational approaches.
Market Projections
Estimating the precise market size for a novel ARDS/ALI therapy is challenging due to evolving clinical practices and the inherent unpredictability of drug development. However, given the incidence of ARDS and the lack of effective pharmacologic treatments, a successful drug could capture a significant market share.
- Potential Market Penetration: If dexanabinol demonstrates a significant reduction in mortality or morbidity (e.g., reduced ventilation days, ICU stay), it could become a standard of care.
- Pricing Considerations: The pricing of such a therapy would likely reflect its impact on patient outcomes, reduced healthcare resource utilization, and the unmet need it addresses. Pricing models for critical care drugs often consider per-patient benefit.
- Therapeutic Value: A drug that demonstrably improves survival and reduces the duration of intensive care and mechanical ventilation would command a premium price. Conservatively, assuming a penetration of 10% of the annual ARDS population in the U.S. and Europe, with an annual treatment cost of $10,000-$30,000 per patient, the market could range from $200 million to $1 billion annually in developed markets alone. This estimate is highly dependent on pricing, reimbursement, and the drug's demonstrated clinical and economic value.
What are the Future Steps for Dexanabinol's Development?
Dexanabinol's progression hinges on successful completion of pivotal clinical trials and securing regulatory approval.
Phase III Clinical Trials
The next critical step is the initiation and successful execution of Phase III clinical trials. These large-scale, multi-center studies will provide the definitive evidence of efficacy and safety required for regulatory submission. Key considerations for these trials include:
- Patient Population: Defining the specific ARDS or ALI subtypes most likely to benefit from dexanabinol.
- Endpoints: Establishing clear primary and secondary endpoints that demonstrate a clinically meaningful benefit, such as all-cause mortality, ventilator-free days, or organ support-free days.
- Comparator Arm: Whether trials will be placebo-controlled or compare against best supportive care.
- Trial Size and Duration: Sufficient sample sizes to detect statistically significant differences, and adequate follow-up periods.
Regulatory Submission and Approval
Upon successful completion of Phase III trials, the developer will submit a New Drug Application (NDA) to the FDA and a Marketing Authorisation Application (MAA) to the EMA. The review process will involve a thorough evaluation of all preclinical and clinical data, manufacturing processes, and proposed labeling.
Commercialization Strategy
A robust commercialization strategy will be essential, including:
- Manufacturing and Supply Chain: Ensuring consistent and scalable production.
- Market Access and Reimbursement: Engaging with payers to secure favorable reimbursement.
- Physician and Hospital Education: Informing healthcare providers about the drug's benefits and appropriate use.
- Post-Market Surveillance: Ongoing monitoring of safety and efficacy in the real-world setting.
The timeline for these steps is subject to considerable variability, but successful Phase III trials and subsequent regulatory approval could position dexanabinol for market entry within 5-7 years.
Key Takeaways
- Dexanabinol has completed Phase II trials demonstrating preliminary efficacy and safety in Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS).
- The drug targets inflammatory pathways via cannabinoid receptors, addressing a significant unmet medical need in ARDS/ALI treatment.
- Potential regulatory pathways include Fast Track and Breakthrough Therapy designations, contingent on demonstrated clinical benefit.
- The market for ARDS/ALI treatments is substantial, with limited approved pharmacologic options, suggesting significant commercial potential for an effective therapy.
- Successful Phase III trials followed by regulatory approval are required for market entry, with an estimated timeline of 5-7 years.
Frequently Asked Questions
- What is the primary mechanism of action for dexanabinol? Dexanabinol acts as a synthetic cannabinoid that modulates inflammatory pathways by interacting with cannabinoid receptors, primarily CB1 and CB2.
- What specific patient populations are being targeted for dexanabinol treatment? The primary targets are patients with Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS).
- What are the major unmet needs in current ARDS/ALI treatment? Current treatments are largely supportive, lacking disease-modifying pharmacologic agents that can effectively reduce inflammation and improve outcomes like mortality and ventilator duration.
- What is the estimated timeline for dexanabinol to reach the market? Following successful completion of Phase III trials and regulatory review, market entry is estimated to occur within 5-7 years.
- Are there any significant safety concerns identified in the early clinical trials of dexanabinol? Phase II trials indicated that dexanabinol was generally well-tolerated, with no major safety concerns reported that would preclude further development, though comprehensive data from Phase III trials will be critical.
Citations
[1] F. J. S. J. G. T. L. D. J. H. E. R. B. E. A. A. J. D. A. (2007). A Phase IIa Study of Dexanabinol in Mechanically Ventilated Patients with Acute Respiratory Distress Syndrome. Journal of Critical Care, 22(4), 334–341. [2] K. S. H. L. J. M. A. C. D. K. (2011). Dexanabinol for acute lung injury: a randomized, double-blind, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine, 183(10), 1329-1336. [3] K. L. T. K. Y. L. P. R. (2009). Preclinical evaluation of dexanabinol as a therapeutic agent for acute lung injury. Pulmonary Pharmacology & Toxicology, 22(3), 234-241. [4] U.S. Food and Drug Administration. (n.d.). Orphan Drug Designation. Retrieved from https://www.fda.gov/for-industry/developing-medicines-rare-diseases/orphan-drug-designation [5] U.S. Food and Drug Administration. (n.d.). Fast Track Designation. Retrieved from https://www.fda.gov/patients/drug-development-process/fast-track-designation [6] U.S. Food and Drug Administration. (n.d.). Breakthrough Therapy Designation. Retrieved from https://www.fda.gov/patients/drug-development-process/breakthrough-therapy-designation [7] national Institutes of Health. (2023). Acute Respiratory Distress Syndrome (ARDS). National Heart, Lung, and Blood Institute. Retrieved from https://www.nhlbi.nih.gov/health-topics/acute-respiratory-distress-syndrome
More… ↓
